Award will fund first in human clinical trials of next generation O-GlcNAcase … Continue reading “Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation”
Novo Seeds, the early stage investment and company creation team of Novo … Continue reading “Novo Holdings participates in USD 17 million Series A investment in BioPhero for development of sustainable insect pheromones”
ExeVir, which is developing single domain antibody therapies providing broad protection against … Continue reading “ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV and related coronaviruses”
ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that … Continue reading “ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases”
Biocomposites, an international medical device company that engineers, manufactures and markets world … Continue reading “Biocomposites Appoints Davina Lawrence as National Sales Director”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia”
Enzyre’s diagnostic technology platform will enable patient testing and monitoring of congenital … Continue reading “Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients”
ISA106’s promising results in preclinical tests warrant fast entry into human studies … Continue reading “ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy”
Novo Holdings A/S today announced that it has agreed to acquire Altasciences … Continue reading “Novo Holdings to acquire Altasciences”
Merger of 10 Privately Held Biotech Companies with Highly Validated Programs Led … Continue reading “Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model”
Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing … Continue reading “Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients”
MedLumics, a privately held medical device company developing AblaView®, the first optically-guided … Continue reading “MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman”
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused … Continue reading “Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel”
Destiny Pharma Plc (AIM: DEST) a clinical stage innovative biotechnology company focused … Continue reading “Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board”
Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the first patient has … Continue reading “First Patient Dosed in NefIgArd Open Label Extension Study”
Novo Ventures, the ventures arm of Novo Holdings, today publishes its review … Continue reading “Novo Ventures provides business update on an exceptional year”
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the … Continue reading “Neuraxpharm selected for prestigious pilot program to supply medical cannabis in France”
ISA Pharmaceuticals B.V. today announced that the first patient has been dosed … Continue reading “First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda”
Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), … Continue reading “Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
Spitalfields
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
